Navigation Links
RT-PCR Primer Sets for Human and Mouse Mismatch Repair Genes

Of each PCR reaction, 10 l was run on a 2% agarose, Tris-acetate gel stained with ethidium bromide.

The expected amplification products from human cDNA ranged from 515 to 876 bp. The primer set for hGTBP produced a significant quantity of PCR product as a result of amplification from genomic template, resulting in a 3.5- to 4-kb band. Since this band migrated more slowly than the 515-bp band produced from amplification of cDNA, it is unlikely to cause problems with RT-PCR analysis of cDNA preparations contaminated with genomic DNA. None of the other primer sets resulted in detectable PCR product when amplifying from human genomic DNA template.

figure 2

A similar experiment contrasted results using the mouse RT-PCR primer sets to amplify either mouse liver cDNA or mouse genomic DNA templates (figure 2). The expected mouse cDNA-derived products in this group ranged from 504 to 926 bp. None of the mouse primer sets amplified a visible product from genomic mouse DNA template when reactions were performed at the recommended annealing temperature.

Conclusions

Characterization of mammalian DNA repair enzymes is a rapidly advancing field. To meet the needs of researchers studying these pathways, Stratagene has developed RT-PCR primers sets for the newly identified genes involved in mammalian DNA mismatch repair. These primers sets amplify regions that span intron-exon boundaries, minimizing the effects of amplification from contaminating genomic DNA template. Each primer set includes resource information for the derivation of the primer set.

REFERENCES
  1. Freidberg, E.C., et al. (1995) In DNA Repair and Mutagenesis, pp.367-368. ASM Press, Washington, D.C.

  2. Karran, P.
    '"/>



Source:


Page: All 1 2 3 4 5

Related biology technology :

1. New Kit Generates Exceptionally Pure Total RNA for RT-PCR
2. Brilliant Core Reagent Kits for QPCR and QRT-PCR
3. Control RT-PCR Primers for Human Gene Transcripts with Varying Abundance
4. prostar RT-PCR Systems for Robust High-Fidelity RNA Amplification
5. Performance Comparisons of Commercial RT-PCR Systems
6. RT-PCR Primers for the Study of Apoptosis
7. cMaster RTplusPCR System for increased sensitivity and product length in RT-PCR
8. Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf cMaster RTplusPCR System
9. Optimized Dengue RT-PCR
10. QuantiTect SYBR Green RT-PCR Kit
11. C. therm. Polymerase One-Step RT-PCR System

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: PCR Primer Sets for Human and Mouse Mismatch Repair Genes

(Date:11/6/2009)... CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolyti...s" or the "Company") today announced updated resul...) in patients with sarcomas metastatic to the lung...ctive Tissue Oncology Society Meeting held in Miam...ster presentation, entitled "A Phase II Study of I...
(Date:11/6/2009)... The agenda for Arrowhead&rsqu...ence, which is set to take place on February 22-24...s three day conference we will highlight key issue...kers to share their experiences. , ... -- The agenda for Arrowhead’s 2010 Persona...
(Date:11/5/2009)... GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ ...ts financial results for the third quarter ended S...3.6 million ($0.04 per share) for the three months...f $6.8 million ($0.08 per share) in the comparable...ber 30, 2009, GenVec,s net loss was $14.1 million ...
(Date:11/5/2009)... PARSIPPANY, N.J., Nov. 5 DSM Phar...de a manufacturing alliance with Galenix, Saint Je...d commercial scale manufacturing partner for Galen...M and Galenix will collaborate on business develop...ery technologies, based on the strength of Galenix...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
... Calif., July 31 Alsius Corporation,(Nasdaq: ALU...ture,management (IVTM(TM)) therapies for criticall...a conference call to discuss the Company,s,second ...ll Worthen,president and CEO, will host the call b...ern Time) on Thursday, August 7. A press release f...
... Colo., July 31 Sierra Neuropharmaceuticals,Inc.,...-brain treatment of,neurological diseases, announc...ing. Co-leads in the funding were HealthCare Ventu...tners. Other investors include High Country,Ventur...etary drug development process that makes use of,s...
...OWN, Pa., July 31 The Quigley,Corporation (Nasdaq...,operations of $2.1 million, for the second quarte...orted for the second quarter ended June 30,2007. F...ere $7.4 million,compared to $8.4 million reported...t sales were influenced by distribution changes an...
Other Biology Technology:Alsius Corporation to Host Second Quarter 2008 Financial Results Conference Call on August 7 2Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round 2Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round 3The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 2The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 3The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 4The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 5The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 6
(Date:11/9/2009)... Naturwissenschaften is publishing a special issu...ology" to commemorate Darwin,s On the Origin of Sp...r 1859. Guest editor and author of the lead articl...iology and evolutionary biology at the University ... issue are available free of charge until 30 Decem...
(Date:11/9/2009)..., November 09, 2009 / b3c newswire / - Today, T...venth Wave, an American organization for contract ...ies have signed a letter of intent with regard to ...M. The letter of intent proposes a collaboration i...or commercialization in North America. The TIM sys...
(Date:11/8/2009)...d. - Researchers at Purdue University have discove...ers in spinal cord injuries using nano-spheres tha...n accident. , The synthetic "copolymer micelles"...diameter, or roughly 100 times smaller than the di...een studying how to deliver drugs for cancer treat...
Breaking Biology News(10 mins):TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3AcelRx Announces Perfect Performance of Handheld Component of ARX 01 Sufentanil NanoTab PCA System in a Phase 2 Study 52359 1AcelRx Announces Perfect Performance of Handheld Component of ARX 01 Sufentanil NanoTab PCA System in a Phase 2 Study 52359 2AcelRx Announces Perfect Performance of Handheld Component of ARX 01 Sufentanil NanoTab PCA System in a Phase 2 Study 52359 3Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 1Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 2Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 3Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 4Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 5Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 6Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28 2009 13135 1Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28 2009 13135 2
... nutritious and tasty, but don’t count on them to ...er Epidemiology, Biomarkers & Prevention, rese... Fred Hutchinson Cancer Research Center report tha...tomatoes, does not effectively prevent prostate ca...on between beta-carotene, an antioxidant related t...
... Universitat Autònoma de Barcelona (UAB), in coope...-chemical biosensor which detects the presence, in...he most widely used herbicides in agriculture and ...vironment- as well as antibiotics in food. The bio...the expensive laboratory methods which are used to...
...ar symmetrical at first glance, but we,re full of ... up a pencil or throw a baseball, to where languag... our internal organs, humans are a glut of asymmet...norhabditis elegans has nerves on its left and rig...ndedness, the determination of which nerves develo...
Other Biology News:No magic tomato? Study breaks link between lycopene and prostate cancer prevention 2A new portable biosensor detects traces of contaminants in food more quickly and cheaply 2Left-right wiring determined by neural communication in the embryonic worm 2
Rabbit Anti-Human DNase II Polyclonal Antibody, Unconjugated from Calbiochem
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes from BD Biosciences - Discovery Labware
BD BioCoat Collagen I 60 mm Culture Dishes from BD Biosciences - Discovery Labware
Corning C ulture Dishes,100X20 mm,55Cm2,Sterile,6-Pack Carrier (6Pks Of 10 Dishes) from Sigma-Aldrich
Biology Products: